Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Blood (2024) 144 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2024-208727

Published: 2024

Journal Articles

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Chan Y. Cheah, Amanda Jane Johnston, Joel Wight, Piers Blombery, Katharine L. Lewis, Rory Bennett, Jing Xie, Stella Vlahos, Joyce Gonzales, Sally Binks, John F. Seymour

Blood (2024) 144 (Supplement 1): 4410.

https://doi.org/10.1182/blood-2024-199108

Published: 2024

Journal Articles

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Ing Soo Tiong, Satwica Yerneni, Tamia Nguyen, Adam Ivey, Natasha S. Anstee, Emma Palfreyman, Ashish Bajel, Emad Uddin Abro, Devendra Hiwase, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 51.

https://doi.org/10.1182/blood-2024-201145

Published: 2024

Journal Articles

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

Blood (2024) 144 (Supplement 1): 303.

https://doi.org/10.1182/blood-2024-209378

Published: 2024

Journal Articles

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma

Katharine L. Lewis, Pratyush Giri, Tamara Marconi, Piers Blombery, Colm Keane, Nagendra Prasad Sungala, Tara Cochrane, Chun Kei Kris Ma, Vinay Vanguru, Kate Manos, Roslyn Francis, Mannu Walia, Julia Carlson, Belinda E Butcher, Chan Y. Cheah

Blood (2024) 144 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2024-204317

Published: 2024

Journal Articles

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Blood (2024) 144 (Supplement 1): 1318.

https://doi.org/10.1182/blood-2024-208841

Published: 2024

Journal Articles

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Zhi Han Yeoh, Ing Soo Tiong, Mark R Dowling, Hamish W Scott, Nicole O'Leary, Samantha van der Linde, Tamia Nguyen, Simon J Harrison, Ashish Bajel, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 653.

https://doi.org/10.1182/blood-2024-204494

Published: 2024

Journal Articles

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Blood (2024) 144 (Supplement 1): 582.

https://doi.org/10.1182/blood-2024-204930

Published: 2024

Journal Articles

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Lucy C Fox, Nicole Den Elzen, Erin Goode, Kelsey Man, Lin Cheng, Stephanie Best, Jillian Francis, Laura Barth, Paul James, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2024) 144 (Supplement 1): 5015.

https://doi.org/10.1182/blood-2024-202704

Published: 2024

Journal Articles

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, Edward Ayoub, Marietta Truger, Manja Meggendorfer, Miriam Lenk, Gregor Hoermann, Stephan Hutter, Heiko Müller, Wencke Walter, Martha-Lena Müller, Niroshan Nadarajah, Piers Blombery, Ulrich Keller, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach

Blood (2024) 143 (12): 1139–1156.

https://doi.org/10.1182/blood.2023021199

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Lucy C. Fox, Nicole Den Elzen, Laura Barth, Kelsey Man, Paul James, Jillian Francis, Lin Cheng, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2023) 142 (Supplement 1): 369.

https://doi.org/10.1182/blood-2023-177593

Published: 2023

Journal Articles

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Rithin Nedumannil, Tal Karmi, Piers Blombery, Charlotte Hughes, Jeff Szer, David S. Ritchie, Lynette C.Y. Chee

Blood (2023) 142 (Supplement 1): 629.

https://doi.org/10.1182/blood-2023-174666

Published: 2023

Journal Articles

Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress

Katharine L. Lewis, Piers Blombery, Nagendra Prasad Sungala, Chun Kei Kris Ma, Pratyush Giri, Vinay Vanguru, Tara Cochrane, Joanna Katarzyna Czerwinski, Denise Lee, Nada Hamad, Roslyn Francis, Mannu Walia, Julia Carlson, Belinda E Butcher, Chan Y. Cheah

Blood (2023) 142 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2023-185160

Published: 2023

Journal Articles

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 6939.

https://doi.org/10.1182/blood-2023-178806

Published: 2023

Journal Articles

Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma

Imogen Caldwell, Yan Zhuang Yap, Mark R Dowling, Javad Saghebi, Aaron Jun Ning Wong, Roxane Legaie, Rainier Arnolda, Clarissa Wilson, Danielle Ignacio, Nicole O'Leary, Stephanie Yaung, Bowdoin Su, Corinna Woestmann, Michael Dickinson, Ella Thompson, Piers Blombery

Blood (2023) 142 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2023-182999

Published: 2023

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Blood (2023) 141 (7): 800–805.

https://doi.org/10.1182/blood.2022017874

Published: 2023

Includes: Supplemental data

Journal Articles

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Blood (2023) 141 (6): 634–644.

https://doi.org/10.1182/blood.2022016090

Published: 2023

Includes: Supplemental data

NARROW

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only